MedTrace Logo

Corticosteroids to Treat Pancreatitis

NCT05160506 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2026-02-18

No results posted yet for this study

Summary

This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.

Conditions

  • Pancreatitis
  • Pancreatitis, Acute
  • Corticosteroid
  • Hydrocortisone

Interventions

DRUG

Hydrocortisone

Hydrocortisone is a steroid (corticosteroid) medication.

DRUG

Placebo

50ml of 0.9% NACL will serve as the placebo

Sponsors & Collaborators

Principal Investigators

  • Michael Donnino, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-06
Primary Completion
2027-01-31
Completion
2027-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05160506 on ClinicalTrials.gov